Joint HIS & BSAC Spring Meeting 2012: Multi-drug resistant Gram negative infections

Joint HIS & BSAC Spring Meeting 2012
Multi-drug resistant Gram negative infections
Tuesday 20 March
Royal College of Physicians, London

Multidrug-resistant Gram-negative bacterial infections are an area of significant unmet medical need.Most health professionals are seeing rising numbers of these infections in our critical care units and face increasingly difficult challenges of defining appropriate treatment and preventing spread.

To view the programme from the 2012 Joint HIS/BSAC Spring Meeting click here.

Supported by:

Pfizer: Working Together for a Healthier World™
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. In the UK, Pfizer has its European R&D headquarters at Sandwich and its UK business headquarters in Surrey, and is the major supplier of medicines to the NHS.

To learn more about our commitments, please visit us at